Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;66(9):1173-7.
doi: 10.1136/ard.2006.062984. Epub 2007 Jan 9.

Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality

S A Chambers  1 , S C Charman, A Rahman, D A Isenberg
Affiliations

Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality

S A Chambers et al. Ann Rheum Dis. 2007 Sep.

Abstract

Objectives: To determine the prevalence of other autoimmune diseases (AID) in black, Caucasian and South Asian patients with systemic lupus erythematosus (SLE) compared with the prevalence of these AID in the UK population, and to assess the impact of these additional AID on damage scores and mortality.

Methods: The prevalence and chronology of development of additional AID in SLE patients was determined by case note review. Comparisons were made with prevalence data for AID in the general UK population. The impact of additional AID on mortality and damage scores at up to 10 years was determined in the index cases (patients who developed another AID either in the same year or within 5 years of onset of SLE) compared with controls matched for sex, age, ethnicity and year of onset of SLE.

Results: There was no significant difference in the total number of AID that developed in patients from each ethnic group but differences in the frequency of some AID were noted. Mortality and damage scores were worse at 5 years in the study cases than the controls, particularly in the peripheral vascular category.

Conclusion: Patients with SLE might develop other AID that could complicate management of SLE by having an adverse impact on damage scores and mortality.

PubMed Disclaimer

References

    1. Manousssakis M N, Georgopoulou C, Zintzaras E, Spyropolou M, Stavropoulou A, Skopouli F N.et al Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 200450882–891. - PubMed
    1. Kokori S I, Ioannidis J P, Voulgarelis M, Tzioufas A G, Moutsopoulos H M. Autoimmune haemolytic anaemia in patients with systemic lupus erythematosus. Am J Med 2000108198–204. - PubMed
    1. Cervera R, Piette J C, Font J, Khamashta M A, Shoenfeld Y, Camps M T.et al Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002461019–1027. - PubMed
    1. McDonagh J E, Isenberg D A. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 200059230–232. - PMC - PubMed
    1. Vitali C, Bombardieri S, Moutsopoulos H M, Balestrieri G, Benciveli W, Bernstein R M.et al Preliminary criteria for the classification of Sjogren's syndrome. Arthritis Rheum 199336340–347. - PubMed